 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...215216217218219220221222223224225...235236» |
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., floxuridine / Generic mfg.
Trial primary completion date, Metastases: Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer (clinicaltrials.gov) - May 27, 2014
P2, N=49, Completed, Sponsor: City of Hope Medical Center
Trial primary completion date: Sep 2014 --> May 2014
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment change, Combination therapy, Metastases: Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab (clinicaltrials.gov) - May 27, 2014
P1, N=140, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2014 --> May 2014 N=198 --> 140
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial completion, Combination therapy, Metastases: Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab (clinicaltrials.gov) - May 27, 2014
P1, N=140, Completed, Sponsor: M.D. Anderson Cancer Center
N=198 --> 140 Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., floxuridine / Generic mfg.
Trial completion, Metastases: Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer (clinicaltrials.gov) - May 27, 2014
P2, N=49, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: Maintenance Chemotherapy After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer (clinicaltrials.gov) - May 27, 2014
P2, N=35, Recruiting, Sponsor: Marks, John, M.D.
Active, not recruiting --> Completed Trial primary completion date: Aug 2013 --> Aug 2017
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Combination therapy, Metastases: GP28328: A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 27, 2014
P1, N=101, Recruiting, Sponsor: Genentech
Trial primary completion date: Aug 2013 --> Aug 2017 Trial completion date: Jul 2015 --> Sep 2016
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date: Maintenance Chemotherapy After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer (clinicaltrials.gov) - May 27, 2014
P2, N=35, Recruiting, Sponsor: Marks, John, M.D.
Trial completion date: Jul 2015 --> Sep 2016 Trial completion date: Aug 2014 --> Aug 2017
- || SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial primary completion date: SIRFLOX: FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer (clinicaltrials.gov) - May 26, 2014
P=N/A, N=518, Active, not recruiting, Sponsor: Sirtex Medical
Trial completion date: Aug 2014 --> Aug 2017 Trial primary completion date: Apr 2014 --> Sep 2014
- || AL101 / Ayala Pharma
Combination therapy, Metastases: Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors (clinicaltrials.gov) - May 22, 2014
P1, N=96, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Apr 2014 --> Sep 2014 N=60 --> 96
- leucovorin calcium / Generic mfg.
Trial initiation date, Combination therapy: Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - May 21, 2014
P1, N=39, Not yet recruiting, Sponsor: City of Hope Medical Center
N=60 --> 96 Initiation date: Apr 2014 --> Apr 2015
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment open, Metastases: IriGen: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - May 21, 2014
P2, N=47, Recruiting, Sponsor: Centre Jean Perrin
Initiation date: Apr 2014 --> Apr 2015 Active, not recruiting --> Recruiting
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: CHARTA: Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - May 19, 2014
P2, N=250, Recruiting, Sponsor: Martin-Luther-Universit
Active, not recruiting --> Recruiting Trial primary completion date: Jan 2014 --> Jan 2015
- || Avastin (bevacizumab) / Roche
Trial completion date, Combination therapy, Metastases: CHARTA: Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - May 19, 2014
P2, N=250, Recruiting, Sponsor: Martin-Luther-Universit
Trial primary completion date: Jan 2014 --> Jan 2015 Trial completion date: Jan 2016 --> Jan 2017
- | Biomarker, New P2 trial, Metastases: PAMELA70: Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer (clinicaltrials.gov) - May 19, 2014
P2, N=72, Not yet recruiting, Sponsor: Institut Cancerologie de l'Ouest
- ||||| Tepylute (thiotepa ready to dilute) / Shorla Oncology, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed: COG-ACNS0334: Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma (clinicaltrials.gov) - May 19, 2014
P3, N=96, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Jan 2016 --> Jan 2017 Recruiting --> Active, not recruiting
- Trial primary completion date: Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 18, 2014
P2, N=66, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2014 --> Feb 2018
- Avastin (bevacizumab) / Roche
Trial primary completion date: Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer (clinicaltrials.gov) - May 18, 2014
P3, N=2100, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2014 --> Feb 2018 Trial primary completion date: Feb 2013 --> Dec 2012
- | veliparib (ABT-888) / AbbVie
Trial completion date, Combination therapy, Metastases: Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor (clinicaltrials.gov) - May 18, 2014
P1, N=60, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Feb 2013 --> Dec 2012 Trial completion date: Dec 2014 --> Jan 2015
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial, Metastases: Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer (clinicaltrials.gov) - May 18, 2014
P2, N=52, Completed, Sponsor: Seoul National University Hospital
- Enrollment closed, Metastases: Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer (clinicaltrials.gov) - May 18, 2014
P2, N=67, Active, not recruiting, Sponsor: Yale University
Trial completion date: Dec 2014 --> Jan 2015 Recruiting --> Active, not recruiting
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 18, 2014
P2, N=77, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2017 --> Jun 2016
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial primary completion date: Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors (clinicaltrials.gov) - May 18, 2014
P2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2017 --> Jun 2016 Trial primary completion date: Apr 2014 --> Aug 2014
- || Avastin (bevacizumab) / Roche
Trial completion date, Combination therapy, Metastases: A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 18, 2014
P2, N=77, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Apr 2014 --> Aug 2014 Trial completion date: Jan 2017 --> Jun 2016
- ||||| vanucizumab (RG7221) / Roche, Avastin (bevacizumab) / Roche
New P2 trial, Metastases: McCAVE: A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - May 15, 2014
P2, N=150, Not yet recruiting, Sponsor: Hoffmann-La Roche
- sunitinib / Generic mfg.
Trial completion date, Metastases: SUN-CASE: Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI (clinicaltrials.gov) - May 12, 2014
P2, N=91, Completed, Sponsor: PD Dr Markus M
Trial completion date: Jan 2017 --> Jun 2016 Trial completion date: Nov 2012 --> Jul 2013
- sunitinib / Generic mfg.
Trial completion, Metastases: SUN-CASE: Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI (clinicaltrials.gov) - May 12, 2014
P2, N=91, Completed, Sponsor: PD Dr Markus M
Trial completion date: Nov 2012 --> Jul 2013 Active, not recruiting --> Completed
- thioguanine / Generic mfg.
Trial completion: CINJALL: Treatment for Children With Acute Lymphocytic Leukemia (clinicaltrials.gov) - May 11, 2014
P2, N=60, Completed, Sponsor: Rutgers, The State University of New Jersey
Active, not recruiting --> Completed Terminated --> Completed
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20) (clinicaltrials.gov) - May 11, 2014
P2, N=102, Completed, Sponsor: Centre Hospitalier Universitaire Dijon
Terminated --> Completed Trial primary completion date: Aug 2014 --> Jul 2013
- Trial primary completion date, Metastases: FLOT4: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer (clinicaltrials.gov) - May 11, 2014
P2/3, N=590, Recruiting, Sponsor: Krankenhaus Nordwest
Trial primary completion date: Aug 2014 --> Jul 2013 Trial primary completion date: Jul 2015 --> Aug 2016
- Trial completion date, Metastases: FLOT4: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer (clinicaltrials.gov) - May 11, 2014
P2/3, N=590, Recruiting, Sponsor: Krankenhaus Nordwest
Trial primary completion date: Jul 2015 --> Aug 2016 Trial completion date: Dec 2015 --> Aug 2016
- Avastin (bevacizumab) / Roche
Trial completion, Combination therapy, Metastases: Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20) (clinicaltrials.gov) - May 11, 2014
P2, N=102, Completed, Sponsor: Centre Hospitalier Universitaire Dijon
Trial completion date: Dec 2015 --> Aug 2016 Recruiting --> Completed
- |||||||||| MB-6 / Microbio
New P3 trial, Surgery: A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer. (clinicaltrials.gov) - May 8, 2014
P3, N=184, Recruiting, Sponsor: Microbio Co Ltd
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study (clinicaltrials.gov) - May 7, 2014
P1, N=35, Recruiting, Sponsor: Brown University
Recruiting --> Completed Trial primary completion date: Jul 2013 --> Jul 2014
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial initiation date, Metastases: BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - May 7, 2014
P2, N=50, Not yet recruiting, Sponsor: howard safran
Trial primary completion date: Jul 2013 --> Jul 2014 Initiation date: Mar 2014 --> Jun 2014
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date: BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study (clinicaltrials.gov) - May 7, 2014
P1, N=35, Recruiting, Sponsor: Brown University
Initiation date: Mar 2014 --> Jun 2014 Trial completion date: Nov 2013 --> Nov 2014
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change: BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study (clinicaltrials.gov) - May 7, 2014
P1, N=28, Recruiting, Sponsor: Brown University
Trial completion date: Nov 2013 --> Nov 2014 N=18 --> 28
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
Trial completion date, Metastases: Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - May 6, 2014
P1/2, N=24, Active, not recruiting, Sponsor: New York University School of Medicine
N=18 --> 28 Trial completion date: Dec 2013 --> Dec 2014
- Erbitux (cetuximab) / Eli Lilly
Trial primary completion date: A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver (clinicaltrials.gov) - May 6, 2014
P2, N=20, Active, not recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Trial completion date: Dec 2013 --> Dec 2014 Trial primary completion date: Jun 2013 --> Jul 2013
- Erbitux (cetuximab) / Eli Lilly
Trial completion date: A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver (clinicaltrials.gov) - May 6, 2014
P2, N=20, Active, not recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Trial primary completion date: Jun 2013 --> Jul 2013 Trial completion date: Jan 2018 --> Dec 2015
- Cyramza (ramucirumab) / Eli Lilly
Trial initiation date, Metastases: A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer (clinicaltrials.gov) - May 5, 2014
P1, N=9, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Jan 2018 --> Dec 2015 Initiation date: Mar 2014 --> Apr 2014
- 5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) - May 5, 2014
P2, N=43, Recruiting, Sponsor: Case Comprehensive Cancer Center
Initiation date: Mar 2014 --> Apr 2014 Trial primary completion date: Mar 2014 --> Sep 2014
- 5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Metastases: Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) - May 5, 2014
P2, N=43, Recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Mar 2014 --> Sep 2014 Trial completion date: Mar 2014 --> Sep 2014
- Cyramza (ramucirumab) / Eli Lilly
Enrollment open, Metastases: A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer (clinicaltrials.gov) - May 5, 2014
P1, N=9, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Mar 2014 --> Sep 2014 Not yet recruiting --> Recruiting
- |||| Vectibix (panitumumab) / Amgen
Enrollment open: PanaMa: Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - May 5, 2014
P2, N=280, Recruiting, Sponsor: AIO-Studien-gGmbH
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| onartuzumab (RG3638) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer (clinicaltrials.gov) - May 4, 2014
P3, N=800, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2016 --> Aug 2015
- ||| onartuzumab (RG3638) / Roche
Trial completion date, Combination therapy, Metastases: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer (clinicaltrials.gov) - May 4, 2014
P3, N=800, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2016 --> Aug 2015 Trial completion date: Jun 2016 --> Aug 2015
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 30, 2014
P2, N=100, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- ||||| Zaltrap (ziv-aflibercept IV) / Sanofi
New P2 trial, Metastases: AMALTHEA: Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Apr 30, 2014
P2, N=73, Recruiting, Sponsor: Hellenic Cooperative Oncology Group
- | New P2 trial, Metastases: FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 29, 2014
P2, N=164, Recruiting, Sponsor: Sun Yat-sen University
- | Trial completion: AALL0031: Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 28, 2014
P3, N=220, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2016 --> Aug 2015 Active, not recruiting --> Completed